Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Category: Anti-Aging / Telomere. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only / No approved human indication in Western countries
Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends. Its small size allows blood-brain barrier penetration and broad tissue distribution, though oral bioavailability is…
Research base: 0 registered clinical trials and 8 indexed publications reference Epithalon.
Safety considerations: Generally well tolerated; no serious adverse events reported in decades of Russian clinical use; Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported; Mild headaches, dizziness, and GI discomfort possible.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-08-12.
Related peptides: NAD+ (Nicotinamide Adenine Dinucleotide).
Compare: Epithalon vs NAD+ (Nicotinamide Adenine Dinucleotide).
There is no controlled Western clinical evidence that epithalon reverses aging. Claims are based on cell culture, animal studies, and Russian clinical observations primarily from one research group. Animal data shows lifespan extension and multiple Russian clinical reports document benefits, but independent Western verification is lacking.
Telomerase activation is theoretically concerning because cancer cells use telomerase to become immortal. However, Epithalon appears selective for normal cells (does not activate telomerase in cancer cells in available data), and no increased cancer incidence has been documented in decades of clinical use.
Research protocols use 5 mg once daily SC for 20 consecutive days, repeated several times per year (typically 2-3 cycles). Evening administration is recommended. Some protocols use 10-day cycles.
Epithalon enhances melatonin production from the pineal gland and is reported to significantly improve sleep quality, particularly in age-related insomnia, by restoring youthful circadian rhythms.
Epithalon was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, where it has been studied for over 30 years. The majority of published studies come from this group. Independent Western clinical trials remain minimal.